Content about Aegerion Pharmaceuticals

December 27, 2012

Aegerion receives FDA approval for cholesterol drug, with strongest warning

The Food and Drug Administration on Monday approved Aegerion Pharmaceuticals' cholesterol drug, Juxtapid.

CAMBRIDGE, Mass. — The Food and Drug Administration on Monday approved Aegerion Pharmaceuticals' cholesterol drug, Juxtapid.

The drug — an alternative treatment for patients who have a genetic predisposition to high cholesterol — will carry a boxed warning, the strongest level of FDA warning. Juxtapid will be available only through a restricted program due to risk of liver damage.

April 27, 2011

Aegerion appoints new CFO

A biopharmaceutical company has appointed a new CFO.

CAMBRIDGE, Mass. — A biopharmaceutical company has appointed a new CFO.

Aegerion Pharmaceuticals named Mark Fitzpatrick as the company's new CFO. Fitzpatrick joins the company, which is focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, from Proteon Therapeutics, where he served as VP, CFO and assistant secretary.

March 15, 2011

Aegerion's lomitapide granted orphan-drug status by FDA

A drug under investigation as a treatment for a rare genetic disorder that causes abnormally high triglyceride levels in the blood has received orphan-drug designation from the Food and Drug Administration.

CAMBRIDGE, Mass. — A drug under investigation as a treatment for a rare genetic disorder that causes abnormally high triglyceride levels in the blood has received orphan-drug designation from the Food and Drug Administration.